More than one-third of adults in the USA have obesity, which causes, exacerbates or
adversely impacts numerous medical comorbidities, including diabetes mellitus and …

As a chronic and relapsing disease, obesity negatively impacts the health of men to a
greater extent than that of women, with a higher risk of cardiovascular disease. Since …

Objective Development of these guidelines is mandated by the American Association of
Clinical Endocrinologists (AACE) Board of Directors and the American College of …

Background & Aims Pharmacological management of obesity improves outcomes and
decreases the risk of obesity-related complications. This American Gastroenterological …

Objective: To examine the effects of naltrexone/bupropion (NB) combination therapy on
weight and weight‐related risk factors in overweight and obese participants. Design and …

The neurotransmitter transporters (NTTs) belonging to the solute carrier 6 (SLC6) gene
family (also referred to as the neurotransmitter-sodium-symporter family or Na+/Cl …

OBJECTIVE To assess the efficacy and safety of 32 mg naltrexone sustained-release
(SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with …

Background Despite increasing public health concerns regarding obesity, few safe and
effective drug treatments are available. Combination treatment with sustained-release …

In 1998, the National Institutes of Health (NIH) recognized obesity as a disease,
acknowledging its profound effects on individual health outcomes and socioeconomic costs …

The ideal anti-obesity drug would produce sustained weight loss with minimal side effects.
The mechanisms that regulate energy balance have substantial built-in redundancy, overlap …